Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab open-label extension in active axial spondyloarthritis
2019-004163-47Phase 3Active
- Sponsor
- UCB
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by UCB. Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2020; status: active.
02
Drugs
bimekizumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2019-004163-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004163-47.